Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

卡博替尼（Cabozantinib）是一种多激酶抑制剂（MKI），在美国获批用于晚期 HCC 后线治疗。近日，一则发表在 Clin J Gastroenterol 的病例分析描述了一例接受多种方案治疗后进展，而接受卡博替尼单药 6 线治疗达到完全缓解 ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

That takes CTLA4 inhibition into uncharted territory in HCC, as BMS' Yervoy plus Opdivo is FDA-approved only as a second-line treatment after sorafenib, sold by Bayer as Nexavar and also available ...